| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef66274ad97cf177d057bf90e2b47687 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7526e723eb18ad1a4f667a42efbaaf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_337c852e0e377d97d59285f1153df4f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fba24d8092745e019eeef4879f2ec5b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc203a88a1c118ae753b4343faf51d58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94f79238d498fef15ba856caafb0301a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf5cce345c32b99e33c6c4e4ceb57b9e |
| publicationDate |
2022-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022273588-A1 |
| titleOfInvention |
Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate carcinoma |
| abstract |
The present invention provides a monoamine oxidase B (MAO-B) inhibitor compound for use in the prevention or treatment of prostate carcinoma (PCa), wherein no selective MAO-A inhibitor compound is co-administered. In the use, other agents for the treatment of PCa is administered and/or radiotherapy is used for the treatment of PCa together with or alternately with the selective compound MAO-B. Another aspect of the invention is the use of a MAO-B inhibitor compound in the manufacture of a medicament for the treatment of PCa. |
| priorityDate |
2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |